News

The latest from Velocity Clinical Research

An Interview with Gerald Cephas, MD, on Advancing Psychiatric Research and Promoting Equity in Care

October 27, 2025

A research career wasn’t part of Gerald Cephas, MD’s original plan. He trained in general surgery, intending to specialize in pediatrics, but a health setback during residency changed his course. “Toward the end of residency, I got sick,” he explains. “So, long story short, … Read more

Op-ed: How Data is Driving GenAI Solutions in Clinical Trials

October 7, 2025

By Tyler Beasley, Head of Business Intelligence at Velocity Clinical Research The future of successful clinical trials will be written in data. Generative AI (GenAI) is already transforming how Sponsors, CROs, and sites approach research, but the real impact will come when AI is … Read more

Winning Through Scale: How We’re Building Toward $500M Revenue

September 29, 2025

Investors care about many things, but when they say scale, they mean revenue. Two times, five times, ten times… whatever the directive, it’s centered on revenue growth. For leadership teams, the focus on revenue milestones is more nuanced. Each one matters to investors, yes. … Read more

Potential Breakthrough to Preserve Lean Muscle Mass During GLP-1-Induced Weight Loss

September 18, 2025

The loss of lean muscle mass has long been a concern for patients using GLP-1 therapies. New results from the Regeneron Phase 2 COURAGE trial, led by Julio Rosenstock, MD, at Velocity’s site in Dallas, TX, point to a potential solution. The study indicates that combining … Read more

Julio Rosenstock, MD Lead Author of Phase 2 Trial Results Evaluating Orforglipron Published in Diabetes, Obesity and Metabolism

August 18, 2025

Julio Rosenstock, MD, was the lead author of Phase 2 trial results evaluating orforglipron, an oral GLP-1 receptor agonist, published in Diabetes, Obesity and Metabolism. The study found that orforglipron doses of 12 mg and higher significantly improved β-cell function and insulin sensitivity in … Read more

Not All AI Belongs in Clinical Trials. Here’s How We Decide Which Models Do.

August 14, 2025

It’s a cliché at this point to say AI (artificial intelligence) is the future; there are people still struggling to work their smartphones who could tell you that. AI tools are too capable, and the commercial advantage too significant, for them not to become … Read more

Velocity Appoints Dr. Sarah Smiley as Chief Physician Officer

August 8, 2025

Velocity Clinical Research is pleased to announce the appointment of Sarah Smiley, DO, FACP, as its new Chief Physician Officer (CPO), reinforcing the company’s commitment to clinical leadership as it continues to grow its global site network and deepen its therapeutic expertise. Dr. Smiley … Read more

Velocity Appoints Ines Abs as Country Head for Germany, Strengthening European Leadership Amid Market Consolidation

August 1, 2025

Velocity Clinical Research, the world’s leading integrated research site organization, has appointed Ines Abs as its new Country Head of Germany, reinforcing its commitment to growth in Europe at a time when other site networks are retreating from the region. Ines brings over two … Read more

Velocity Clinical Research Partners with Palantir to Solve Clinical Trials’ Payment Headache

July 17, 2025

Velocity Clinical Research, the leading fully integrated site organization, has announced a strategic partnership with Palantir Technologies to automate and streamline the notoriously complex payments reconciliation process in clinical trials. This collaboration marks a milestone in applying advanced artificial intelligence (AI) to one of … Read more

Velocity Recognized as a Top Enrolling Site Network in Q1 2025 by AstraZeneca

July 16, 2025

We’re proud to share that Velocity was named a top enrolling site network for Q1 2025 by AstraZeneca, with the highest number of randomizations across their biopharma portfolio. This recognition is a testament to the dedication of our teams around the world who work … Read more

Douglas K. Logan, MD, and David Ensz, MD, Author Nature Communications Article

July 3, 2025

Velocity Principal Investigators Douglas K. Logan, MD, and David Ensz, MD, are authors of a newly published Nature Communications article, “Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase.” The Phase 1/2 Moderna trial results “demonstrate the proof of concept that … Read more

An interview with Daniel Williams, DO on Velocity’s PIVOT program and training the next generation of Principal Investigators

July 2, 2025

Very few physicians begin their careers with an eye on research. Moving into the role of Principal Investigator (PI) can be unexpectedly challenging, with demands that often take physicians by surprise. “Much of my experience with clinical research centered around reviewing journal articles for … Read more

Learn more about Velocity's capabilities

Whether you’re ready to conduct a single-site study or a complex, high-volume trial, Velocity will ensure you have the right investigators, clinical staff, and patients for your research program.

Join a remarkable team doing remarkable work

Velocity careers offer competitive pay and benefits, and reward high performance with excellent opportunities.

Whether you're an industry veteran or are looking to take your first step into clinical research, we invite you to apply at Velocity.

Quality. Continuity. Velocity.